Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 12, 2024
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The generic version of Taytulla®1 Capsules, Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, has received approval by the United States Food & Drug Administration.
Product Name : Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Merzee® Capsules in the United States
Details : U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.
Product Name : Merzee
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : dr. J.M. Munster, gynaecologist, principal investigator
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy of Intermittent Versus Daily Oral Iron Supplementation in Anaemic Pregnant Women.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : dr. J.M. Munster, gynaecologist, principal investigator
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®
Details : Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.
Product Name : Gemmily
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Determination of Iron Absorption Mechanism From Ferrous Fumarate With GOS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 24, 2019
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Determination of a Dose-dependent Effect of GOS on Iron Absorption, and Addition of Vitamin C
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 03, 2018
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 30, 2017
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Antistress AG - Burgerstein Vitamine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 18, 2014
Lead Product(s) : Ferrous Fumarate
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable